Long-acting propranolol in the prophylaxis of migraine: a comparative study of two doses

doi:10.1046/j.1468-2982.1990.1002101.x

If you are seeing this message, you may be experiencing temporary network problems. Please wait a few minutes and refresh the page. If the problem persists, you may wish to report it to your local Network Manager.

It is also possible that your web browser is not configured or not able to display style sheets. In this case, although the visual presentation will be degraded, the site should continue to be functional. We recommend using the latest version of Microsoft or Mozilla web browser to help minimise these problems.

Systems Maintenance, Monday, 15th February 2010

Wiley InterScience

Cephalalgia

Volume 10 Issue 2, Pages 101 - 105

Published Online: 19 Jan 2002

Published on behalf of the International Headache Society

Go to Society Site

< Previous Abstract | Next Abstract >

Save Article to My Profile Download Citation Request Permissions

Abstract | Full Text: PDF (Size: 33K) | Related Articles | Citation Tracking

Long-acting propranolol in the prophylaxis of migraine: a comparative study of two doses

JD Carroll ¹ , M Reidy ¹ , PA Savundra ¹ , N Cleave ² , J McAinsh ³

¹ Regional Neurological Unit, Royal Surrey County Hospital, Guildford, Surrey, UK; ² Centre of Mathematical Software Research, University of Liverpool, Liverpool, UK; ³ ICI Pharmaceuticals, Mereside, Alderley Park, Macclesfield, Cheshire, UK

Correspondence to JD Carroll, Regional Neurological Unit, Royal Surrey County Hospital, Guildford, Surrey, UK

ABSTRACT

A randomized double-blind, cross-over study using treatment periods of 12 weeks with a 2-week washout, comparing two long-acting formulations of propranolol ('Inderal'*⁽¹⁾ LA 160 mg daily and Half-'Inderal' LA 80 mg daily) was performed after a placebo run-in of 4 weeks on 51 patients. The study indicated that both long-acting formulations were significantly better than placebo in reducing the frequency of migraine attacks (p < 0.01). After 12 weeks there was a significantly lower (p=0.03) frequency of migraine attacks in patients on the higher dose formulation than in those on the lower dose formulation. There was no significant difference in the frequency of side effects produced by the two formulations.

Accepted 31 October 1989

DIGITAL OBJECT IDENTIFIER (DOI)

10.1046/j.1468-2982.1990.1002101.x About DOI